Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype Background and aim: Losartan is metabolized by polymorphic CYP2C9 to E-3174. Our aim was to evaluate the pharmacokinetics of losartan and E-3174 in relation to the CYP2C9 genotype. Methods: A 50-mg oral dose of losartan was given to 22 Swedish volunteers with different CYP2C9 genotypes. Losartan and E-3174 were analyzed by HPLC in plasma and urine samples collected up to 24 hours after drug intake. Furthermore, losartan and E-3174 were analyzed in 8-hour urine samples collected from 17 Spanish subjects after a single oral dose of 25 mg losartan.
Cytochrome P4502C9 (CYP2C9) plays an important role in the metabolism of about 20 therapeutically used drugs, including S-warfarin, phenytoin, tolbutamide, glipizide, glyburide (INN, glibenclamide), torsemide (INN, torasemide), losartan, and several nonsteroidal anti-inflammatory drugs. [1] [2] [3] The CYP2C9 gene is polymorphic. † CYP2C9*2 (Cys144Ile359) and CYP2C9*3 (Arg144Leu359) code for an enzyme with decreased activity compared with the most common allele CYP2C9*1 (Arg144Ile359). [4] [5] [6] The frequencies of CYP2C9*2 and CYP2C9*3 have been determined in various white (0.08 to 0.12 and 0.03 to 0.08, respectively) and Asian (0 and 0.02 to 0.03, respectively) populations. l, 7, 8 The clinical importance of the CYP2C9 polymorphism has been studied for warfarin, tolbutamide, glipizide, and phenytoin. 6,9-11 Aithal et al 11 reported an overrepresentation of patients with the CYP2C9*2 or CYP2C9*3 allele among those treated with low doses of warfarin (<0.5 mg/day). In 2 studies, the mean maximal elimination rate of phenytoin was about 33% and 42% lower in Japanese epileptic patients with the CYP2C9*1/*3 genotype than the rate in a CYP2C9*1/*1 group. 10, 12 Adverse reactions of phenytoin have also been related to the CYP2C9*3 variant. 13, 14 Two additional mutations in the CYP2C9 gene have been identified recently, but their frequency in different populations and their functional importance remain to be clarified. 15, 16 Unlike CYP2D6, the 4-hydroxylase of debrisoquin (INN, debrisoquine), and CYP2C19, the 4´-hydroxylase of S-mephenytoin, there is no well-established probe for assessment of CYP2C9 activity in vivo. 17, 18 Tolbutamide 19-21 and phenytoin 22 have been suggested as possible probes, but neither of them is optimal for routine phenotyping purposes because of a risk of side effects (central nervous system toxicity after phenytoin administration and hypoglycemia with tolbutamide), relatively elaborate procedure (requirement of blood sampling with phenytoin 22 ), or low sensitivity (ie, lack of bimodality with tolbutamide 20 or limited value of urinary phenytoin metabolic ratio 23 ).
Losartan is a selective angiotensin II receptor antagonist used in the treatment of hypertension and heart failure. 24 It undergoes CYP-mediated oxidative metabolism. 25, 26 Its active metabolite E-3174 is formed by CYP2C9 and CYP3A4 in vitro. 25, 26 We have recently shown that the role of CYP3A4 is negligible at concentrations of losartan lower than 1 µmol/L, corresponding to therapeutic plasma levels. 27 Drug interaction studies support this observation. Fluconazole, a potent CYP2C9 inhibitor in vitro, inhibited the formation of E-3174 and increased the steady-state plasma levels of losartan in healthy volunteers. 28, 29 However, itraconazole, reported to inhibit the metabolism of CYP3A4 substrates, had no effect on losartan oxidation. 28 The aim of this study was to investigate the pharmacokinetics of losartan in relation to the CYP2C9 genotypes in healthy volunteers and to evaluate the possibility of using losartan as a phenotyping probe for CYP2C9.
MATERIAL AND METHODS
Subjects. The plasma pharmacokinetics and urinary excretion of losartan and its metabolite E-3174 were studied in 11 female and 11 male healthy volunteers (age range, 25 to 54 years; weight range, 52 to 91 kg) selected from a population of 430 white Swedish subjects previously genotyped for the CYP2C9 polymorphism. 8 The subjects were selected to include all known genotypes of CYP2C9 with regard to the Arg144Cys and Ile359Leu mutations: CYP2C9*1/*1 (6 subjects), *1/*3 (5 subjects), *1/*2 (3 subjects), *2/*3 (4 subjects), *2/*2 (3 subjects), and *3/*3 (1 subject). Our aim was to include 5 to 6 subjects in each genotype group but because of the low frequency of the CYP2C9*2 and CYP2C9*3 alleles, these numbers could not be reached in the rare genotype groups. In addition, urinary excretion of losartan and E-3174 was studied in 10 female and 7 male Spanish subjects (age range, 21-53 years; weight range, 45-90 kg) with the genotypes CYP2C9*1/*1 (n = 8), *1/*2 (n = 2), *1/*3 (n = 5), and *3/*3 (n = 2). The genotypes were analyzed by determination of the CYP2C9*2 and CYP2C9*3 alleles as described previously. 8 In brief, polymerase chain reaction amplification was performed with use of the primers described by Sullivan-Klose et al, 6 after which the products were digested by the endonucleases AvaII and NsiI for the CYP2C9*2 and CYP2C9*3 alleles, respectively.
All subjects were healthy as assessed by medical history, physical examination, and clinical laboratory test results of hematologic, liver, and kidney function; blood tests for human immunodeficiency virus and hepatitis B and C; electrocardiograms, and urine screenings for drugs of abuse. Written informed consent was obtained from the volunteers. The study was approved by the local ethics committees at Huddinge University Hospital (Stockholm, Sweden) and Extremadura University Hospital (Badajoz, Spain) and was conducted in accordance with the Declaration of Helsinki.
Study design. The 22 Swedish subjects received a single 50-mg oral dose of losartan (Cozaar, Merck Sharp & Dohme Ltd) after an overnight fast. They had not taken any medication for at least 2 weeks before losartan administration. Venous blood samples (10 ml) were obtained before (0 hour) and at 1 ⁄2, 1, 1 1 ⁄2, 2, 4, 6, 8, 10, 12, and 24 hours after drug intake for the determination of losartan and E-3174 concentrations. The samples were collected in heparinized Vacutainer blood-collecting tubes (Terumo Europe NV 3001, Leuven, Belgium) and centrifuged. Plasma was separated and stored at -20°C until analysis. A baseline urine sample and all urine voided during 24 hours after drug administration was collected in fractions from 0 to 4, 4 to 8, 8 to 12, and 12 to 24 hours. A standardized lunch was served following 4 hours of fasting after drug intake. Blood pressure was measured concomitantly with blood sampling while the subjects were in the supine position. The 17 Spanish volunteers received a single 25-mg oral dose of losartan (Cozaar) after 3 to 4 hours of fasting, and 0-to 8-hour urine was collected overnight. All side effects reported by the subjects were recorded.
Drug analysis. Losartan, E-3174, and the internal standard (L-158) were supplied by Merck & Company Inc (West Point, Pa). Plasma and urine samples were analyzed for losartan and its metabolite E-3174 mainly as described by Ritter et al. 30 In brief, 0.5 ml plasma was extracted with 8 ml methyl t-butyl ether, followed by reextraction of losartan and E-3174 to 200 µl of 0.05 mol/L sodium hydroxide that was acidified with a citrate buffer and washed with hexane. After addition of isopropanol (25 µl) to 150 µl of the reextracted water phase, a 75-µl aliquot was injected into an HPLC through a Zorbax SB-phenyl column (4.6 mm internal diameter × 25 cm) (Agilent Technologies, USA) and a precolumn filter (Rheodyne LP, Cotati, Calif). The mobile phase consisted of 10-mmol/L sodium dihydrogen phosphate at pH 2.3 and acetonitrile (62:38 [vol/vol]), with a flow rate of 1.0 ml/min. The compounds were detected with fluorescence detection at excitation and emission wavelengths of 250 and 370 nm. Urine samples were centrifuged at 3000g for 5 minutes, and 100 µl was mixed with 0.05-mol/L sodium hydroxide (100 µl), 0.5-mol/L citrate buffer at pH 4.3 (50 µl), and isopropanol (50 µl). Then 30 µl of this solution was injected into the HPLC as described. Standard curves were analyzed in the range from 25 to 2000 nmol/L for both losartan and E-3174 in plasma and urine. The limits of quantification for losartan and E-3174 were 10 nmol/L and 5 nmol/L in plasma, and 20 nmol/L and 10 nmol/L in urine, respectively. The coefficients of variation were calculated for the 50-and 500-nmol/L concentrations. The coefficients of variation of losartan and E-3174 were less than 10% and 6% in plasma and 10% and 8% in urine, respectively.
Acetonitrile, isopropanol, hexane, sodium citrate, citric acid, sodium hydroxide, 85% orthophosphoric acid, and sodium dihydrogen phosphate were all purchased from Merck KGaA (Darmstadt, Germany). Methyl tbutyl ether was obtained from Labscan Ltd (Dublin, Ireland). Pharmacokinetic and statistical analysis. The maximum plasma concentration (C max ) and the time at which C max occurred (t max ) were obtained directly from the concentration-time data for losartan and E-3174. The total area under the plasma concentration versus time curve (AUC total ) was calculated by use of the trapezoidal rule and was extrapolated to infinity by use of the terminal linear part of the curve. The mean infinite area of total was 7.6% and 5.8% for losartan and E-3174, respectively. The apparent terminal elimination half-life (t1 ⁄2 ) was calculated by linear regression analysis from the terminal linear part of the plasma concentration versus time curves. Urinary recovery was calculated on the basis of the excreted amounts of losartan and E-3174 during 24 hours. The pharmacokinetic parameters and the plasma and urinary losartan/E-3174 ratios were logtransformed and first analyzed by 1-way ANOVA. If the overall F ratio was significant, further comparison of the means was performed with the Student t test.
The Spearman rank correlation (r S ) test was performed to evaluate the association between the plasma and urinary losartan/E-3174 ratios. Statistical analysis was done in Statistica 4.3 (StatSoft Inc, Tulsa, Okla), and significance was assumed when P < .05.
RESULTS
All subjects completed the study. One subject with the CYP2C9*1/*3 genotype reported dizziness and had decreased blood pressure (from 111/77 mm Hg to 95/59 mm Hg) and pulse rate (down to 39 beats/min) 4 to 6 hours after intake of 50 mg losartan. The blood pressures of the other subjects did not change significantly during the 24-hour study period compared with the blood pressure values before drug intake. Two subjects (CYP2C9*3/*3 and *2/*3 genotypes) who were taking 50 mg losartan reported slight headaches during the fasting period before lunch. No adverse effects were reported by the subjects who were taking a single oral dose of 25 mg losartan. Plasma pharmacokinetics. Fig 1 shows the plasma profiles of losartan and E-3174 in the CYP2C9*1/*1 and CYP2C9*2/*2 genotype groups and the CYP2C9*3/*3 subject after a single oral dose of 50 mg losartan. Compared with the CYP2C9*1/*1 genotype group, the plasma concentrations of E-3174 were markedly decreased in the subject with the CYP2C9*3/*3 genotype but not in the CYP2C9*2/*2 genotype group. The concentrations of losartan did not differ significantly between the genotypes.
The pharmacokinetic parameters of losartan and E-3174 in the different genotype groups are shown in Table I . There were no significant differences in any of the pharmacokinetic parameters of losartan. The C max of E-3174 was significantly lower in the CYP2C9*1/*3 and CYP2C9*2/*3 groups compared with the CYP2C9*1/*1 and the CYP2C9*1/*2 groups (Table I ). The subject with the CYP2C9*3/*3 genotype had the lowest C max for E-3174. The C max in the CYP2C9*2/*2 genotype group was in the range of that in the CYP2C9*1/*1 genotype group. The t max of losartan and E-3174 did not differ between the genotypes (data not shown). The t1 ⁄2 of E-3174 was significantly longer in the CYP2C9*2/*3 and CYP2C9*1/*3 groups compared with the CYP2C9*1/*1 group (Table I ). The AUC total of both losartan and E-3174 showed large intragroup variations but no significant differences between the genotype groups. However, similar to the C max data, the subject with the CYP2C9*3/*3 genotype had the lowest AUC total of E-3174 (Table I) .
The ratio of the losartan plasma AUC total to the E-3174 plasma AUC total was used as a measure of the conversion of losartan to E-3174. This ratio was about 30-fold higher in the CYP2C9*3/*3 subject than in the CYP2C9*1/*1 group (Table I) . A significantly higher ratio was found in the CYP2C9*1/*3 group (approximately 2-fold) compared with the CYP2C9*1/*1 group, as well as in the CYP2C9*2/*3 group compared with the CYP2C9*1/*1, CYP2C9*1/*2, and CYP2C9*1/*3 genotype groups (2-to 3-fold). No difference was observed between the CYP2C9*2/*2 and the CYP2C9*1/*1 groups (Table I) .
Urinalysis. The recovery of losartan as the parent compound and E-3174 in the 24-hour urine specimens after administration of 50 mg losartan was 11% of the dose in the CYP2C9*1/*1 group and 4% to 5% in the other genotype groups (Table II) . This difference was not statistically significant (P = .1). Similar to the plasma data, the urinary recovery of both losartan and E-3174 showed a 9-to 10-fold variation within the CYP2C9*1/*1 group, whereas the interindividual variation was lower in the other genotype groups. The recovery of E-3174 was up to 60-fold lower in the CYP2C9*3/*3 subject than in the subjects in the other genotype groups. A significant correlation (r S = 0.76 and r S = 0.78; P < .001) was found between the urinary losartan/ E-3174 ratio (0-to 8-hour and 0-to 24-hour fractions, respectively) and the plasma AUC ratio (Fig 2) . The losartan/E-3174 ratio in 0-to 8-hour urine from the 22 Swedish subjects was significantly higher in the CYP2C9*2/*3 group compared with the CYP2C9*1/*1, *1/*2, *1/*3, and *2/*2 groups (P < .05), as well as in the CYP2C9*1/*3 group compared with the *1/*1 and *1/*2 groups (P < .05; Table II ). The CYP2C9*3/*3 subject had an extremely high ratio.
The losartan/E-3174 ratios in 0-to 8-hour urine samples from the 17 Spanish volunteers who received a 25-mg dose of losartan are summarized in Table III . The ratios were similar to those found in the Swedish volunteers (Table II) . Approximately 2-fold higher losartan/E-3174 ratios were detected in the CYP2C9*1/*3 group compared with the CYP2C9*1/*1 group (P < .01). The CYP2C9*3/*3 subjects (n = 2) had extremely high ratios that were similar to the ratio found in the Swedish CYP2C9*3/*3 volunteer. In Table IV the urinary ratios from Spanish and Swedish volunteers are compiled. The urinary ratios in the CYP2C9*3/*3 group (n = 3) were extremely high compared with all other genotypes. A significant difference was also observed in the *1/*3 group compared with the *1/*1 and *1/*2 groups. No significant differences were found in the CYP2C9*2/*2 or *1/*2 group compared with the other genotypes. However, the CYP2C9*2/*3 group had approximately 3 and 2 times higher ratios than the *1/*1 and *1/*3 groups, respectively.
DISCUSSION
This study evaluated the pharmacokinetics of losartan for the first time in all the known genotypes of CYP2C9 with regard to the CYP2C9*2 and CYP2C9*3 variant alleles. Our aim was to include 5 to 6 subjects in each genotype group. However, because of the low frequency of individuals who are homozygous for the CYP2C9*2 and CYP2C9*3 alleles in the Swedish population, 8 this aim could not be achieved. For the same reason, most other studies have included only subjects who were heterozygous for these mutated alleles. After screening 430 Swedish and 138 Spanish healthy volunteers, we were able to recruit 3 subjects who were homozygous for *3, 4 subjects who were homozygous for *2, and 4 subjects who carried both these variant alleles. Obviously, the small number of these subjects is a drawback in our study. However, together with the data from heterozygous subjects, these data are of high interest.
Both plasma and urine losartan/E-3174 ratios were significantly higher in the CYP2C9*1/*3 genotype group than in the CYP2C9*1/*1 group (Tables I  through IV) . The ratios in the subjects with CYP2C9*3/*3 genotype were extremely high compared with all the other subjects included in the study. These findings indicate the functional importance of the CYP2C9*3 allele in the oxidation of losartan. The present pharmacokinetic data from the CYP2C9*3/*3 subjects are in close agreement with a previous case report that showed deficient conversion of losartan to E-3174 in 1 subject with the CYP2C9*3/*3 genotype. 31 The effect of the CYP2C9*2 variant was not as evident as that of CYP2C9*3. There was a slight, but statistically nonsignificant, increase of plasma and urinary losartan/E-3174 ratios in the CYP2C9*2/*2 group compared with the CYP2C9*1/*1 group (Tables I through  IV) . However, in subjects with the CYP2C9*2/*3 genotype the conversion of losartan to E-3174 was lower than that in the CYP2C9*1/*3 group. This indicates that the CYP2C9*2 allele has an impact on CYP2C9 activity and also on the metabolism of losartan to E-3174. It can be concluded from these data that the CYP2C9*3 variant has a more pronounced effect than the CYP2C9*2 allele on losartan oxidation in vivo. Other studies have shown similar results with other CYP2C9 substrates, such as warfarin, tolbutamide, and phenytoin. 6, 13, 32 We have recently clarified the role of CYP2C9 polymorphism in losartan oxidation in vitro. 27 Data were obtained from yeast that expressed the different variants of CYP2C9 and from 25 different genotyped samples of human liver microsomes. Approximately 2-, 3-, and 20-fold lower intrinsic clearance values were found in human liver microsomes from persons with CYP2C9*2/*2, CYP2C9*1/*3, and CYP2C9*3/*3 genotypes, respectively, compared with those with the CYP2C9*1/*1 genotype. Therefore the present in vivo findings are consistent with the in vitro data with regard to the functional importance of CYP2C9 polymorphism and especially the CYP2C9*3 allele in losartan metabolism. Interestingly, immunoblotting of human liver samples revealed that the interindividual variability of CYP2C9 protein levels was at least 6-fold. Because this apparently was independent of the CYP2C9 genotype, unidentified factors that regulate CYP2C9 gene expression are also very important for the individual capacity to metabolize CYP2C9-specific drugs. A phenotyping probe that is highly specific for CYP2C9 would be extremely useful in identification of metabolic outliers to further explore the genetics behind this variability in gene expression.
The observed differences in plasma and urine losartan/E-3174 ratios between the CYP2C9 genotypes (Tables I, III , and IV) and the correlation between the plasma and urine ratios (Fig 2) suggest that the urinary losartan/E-3174 ratio might be used as a measure of CYP2C9 activity. There was, however, a considerable interindividual variability in both plasma and urine ratios within each genotype group and an overlap between groups. Similar overlapping metabolic ratios between homozygous and heterozygous extensive metabolizers have been shown for the other 2 major polymorphic CYPs, CYP2D6 and CYP2C19. 33, 34 The results of this study are therefore not surprising in this respect. However, further studies in larger randomly selected populations are required to establish the relationship between the CYP2C9 genotype and the suggested urinary losartan/E-3174 ratio as a measure of CYP2C9 activity. In particular, these studies should include a number of subjects homozygous for CYP2C9*2 and CYP2C9*3, respectively, and should therefore include several hundred individuals. Tolbutamide and phenytoin have both been suggested as probe drugs for CYP2C9 in vivo. 19, 21 However, the risk of hypoglycemia with tolbutamide and toxicity with phenytoin, especially in subjects with mutated alleles, limits their wide use. 13 The simplicity and sensitivity of the earlier suggested phenotyping procedures are also questionable. A 12-hour blood sampling is required for phenytoin, which is impractical in many clinical situations and in large population studies. 22 The variability in the renal clearance of unchanged phenytoin limits the usefulness of the urinary 5-parahydroxyphenyl-5-phenylhydantoin/phenytoin metabolic ratio. 23 With losartan, decreased blood pressure may be a possible risk. However, no significant blood pressure changes after a single 50-mg oral dose have been reported in pharmacokinetic and drug interaction studies in healthy volunteers. 28, 29, 35, 36 In our study, 1 subject who was heterozygous for CYP2C9*3 experienced dizziness and had decreased blood pressure 4 to 6 hours after drug intake. Whether the adverse effects in this subject were related to drug intake or caused by prolonged fasting could not be judged with certainty. Theoretically, subjects who carry mutated alleles would be expected to have a lower risk of decreased blood pressure because the metabolite E-3174 contributes to the pharmacological effects of the drug. 37 Genotypic differences may partly explain nonresponses to losartan treatment but, to date, no studies have examined this possibility.
No side effects were reported among the subjects given 25 mg losartan. The urinary ratios after the 25-mg dose were comparable to those after the 50-mg dose and showed similar genotype-related differences (Tables II, III, and IV) . A 25-mg dose is therefore suggested for further phenotyping studies.
Large substrate-selective differences that resulted in different functional consequences have been described for the CYP2C9*2 and CYP2C9*3 variants. In a recent in vitro study, CYP2C9*3 was shown to exhibit a decreased catalytic activity compared with CYP2C9*1. 38 The effect of CYP2C9*3, however, varied largely (3-to 30-fold) in extent between 7 different substrates of CYP2C9. 38 The CYP2C9*2 variant has been shown to be associated with reduced intrinsic clearance for S-warfarin 7-hydroxylation, whereas the intrinsic clearance for tolbutamide hydroxylation was largely unaffected. 5 These substrate-specific differences show the importance of choosing a sensitive probe for CYP2C9 polymorphism. However, because of these differences, the data obtained with one substrate may not be directly applicable to other CYP2C9 substrates.
The pharmacokinetic parameters of losartan calculated in this study are in agreement with those reported earlier. 28, 29, 35, 36 The prolonged t1 ⁄2 of E-3174 in CYP2C9*1/*3 and CYP2C9*2/*3 groups might be explained by the elimination-dependent kinetics of the intermediate metabolite E-3179. Losartan is first converted to an intermediate aldehyde metabolite, E-3179, and then with around 7 times higher formation rate to the carboxylic acid metabolite, E-3174. 25, 26 In a slow metabolizer, decreased formation of E-3174 may result in a prolonged t1 ⁄2 of E-3179, which would consequently affect the t1 ⁄2 of E-3174. None of the pharmacokinetic parameters of losartan was significantly different between the genotype groups. This could be because losartan is also metabolized through other pathways 39 that possibly are not dependent on CYP2C9.
In conclusion, the in vivo metabolism of losartan to E-3174 was related to the CYP2C9 genotype. The CYP2C9*3 allele was associated with decreased formation of the metabolite. The observed genotyperelated differences in the urinary losartan/E-3174 ratio after both 25-mg and 50-mg single oral doses of losartan suggest that this might be used as a measure of CYP2C9 activity in vivo. However, population studies involving larger numbers of subjects with different genotypes are warranted to fully characterize the interindividual variability in the metabolic ratio and its relationship to the CYP2C9 genotype.
